Telix Executive and Leadership Team

Kevin Richardson, the Chief Executive Officer (Americas) at Telix, directs all commercial activities and market expansion efforts across the North American region. Richardson manages the deployment of Illuccix, ensuring seamless integration into clinical workflows for prostate cancer diagnostics. By coordinating with regulatory bodies and healthcare providers, the Chief Executive Officer (Americas) drives the adoption of radiopharmaceutical imaging agents. This leadership role involves scaling regional infrastructure to meet rising demand for advanced oncology tools. Kevin Richardson maintains close alignment with global strategy to ensure consistent service delivery and market penetration. Through the optimization of supply chain logistics and clinical partnerships, the Chief Executive Officer (Americas) secures a competitive position for the company within the complex landscape of urologic oncology. Richardson prioritizes operational efficiency to support the broader mission of delivering precision medicine to patients throughout the Americas.

Christian Behrenbruch, the Group Chief Executive Officer & Managing Director at Telix, architects the overarching corporate strategy and global vision for the organization. Behrenbruch oversees the development of the entire theranostics pipeline, spanning urologic, neuro, and musculoskeletal oncology. The Group Chief Executive Officer & Managing Director maintains direct engagement with the Board to ensure long-term value creation and sustainable growth. By fostering international partnerships and guiding research initiatives, Christian Behrenbruch drives the commercialization of molecularly targeted radiation products. This leadership role involves navigating complex regulatory environments and capital markets to maintain the company's status as a leader in biopharmaceuticals. The Group Chief Executive Officer & Managing Director ensures that all regional operations remain synchronized with the core mission of transforming cancer care. Behrenbruch provides the strategic direction necessary to scale the company's global footprint while maintaining rigorous standards for clinical innovation and patient safety.

Darren Smith, the Group Chief Financial Officer at Telix, manages the global financial health and capital allocation strategies for the entire organization. Smith directs financial planning, reporting, and investor relations to ensure transparency and fiscal stability across all international markets. The Group Chief Financial Officer monitors the economic performance of the commercial-stage pipeline, providing the necessary data to support strategic investment in new oncology research. By overseeing treasury functions and risk management, Darren Smith ensures the company maintains the liquidity required for rapid expansion. This leadership role involves close collaboration with the executive team to align financial resources with operational milestones. The Group Chief Financial Officer drives the implementation of robust financial controls that support the company's listing on major stock exchanges. Smith maintains a focus on long-term profitability while balancing the high costs associated with developing and commercializing advanced radiopharmaceutical products.

Michael Didocha, the Chief Financial Officer (Americas) at Telix, manages the regional financial operations and budgetary oversight for the North American market. Didocha directs the financial analysis of regional commercial performance, ensuring that revenue targets for Illuccix align with corporate objectives. The Chief Financial Officer (Americas) oversees regional accounting, tax compliance, and financial reporting to maintain strict adherence to local regulatory standards. By providing detailed financial insights, Michael Didocha supports the regional leadership team in making informed decisions regarding market expansion and resource allocation. This leadership role involves managing the financial aspects of regional partnerships and distribution agreements. The Chief Financial Officer (Americas) ensures that the regional business unit maintains the fiscal discipline required to support the company's broader growth strategy. Didocha focuses on optimizing regional cash flow and cost structures to maximize the impact of the company's commercial activities within the competitive American healthcare sector.

Darren Patti, the Group Chief Operating Officer at Telix, directs the internal scaling and manufacturing processes required to support global product distribution. Patti oversees the complex supply chain logistics necessary for the delivery of time-sensitive radiopharmaceuticals to clinical sites. The Group Chief Operating Officer manages the integration of production facilities to ensure consistent quality and regulatory compliance across all manufacturing stages. By optimizing operational workflows, Darren Patti drives efficiency in the commercialization of the company's diagnostic and therapeutic portfolio. This leadership role involves coordinating with cross-functional teams to streamline the transition from clinical development to market-ready products. The Group Chief Operating Officer ensures that internal systems support the rapid growth of the company's urologic and neuro-oncology programs. Patti maintains a focus on operational excellence to ensure that the company meets the increasing global demand for precision cancer imaging and treatment solutions.

David Cade, the Chief Medical Officer at Telix, directs the clinical development and medical strategy for the entire portfolio of radiopharmaceutical products. Cade oversees the design and execution of clinical trials, ensuring that all research meets the highest standards of scientific rigor and regulatory approval. The Chief Medical Officer manages the medical affairs team to provide clinical expertise to healthcare providers and researchers globally. By leading the development of new therapeutic applications for prostate, kidney, and brain cancers, David Cade drives the innovation pipeline forward. This leadership role involves close collaboration with regulatory agencies to secure approvals for new diagnostic and treatment agents. The Chief Medical Officer ensures that the company's medical strategy remains grounded in patient needs and clinical evidence. Cade provides the scientific leadership necessary to advance the company's mission of transforming cancer care through the application of molecularly targeted radiation.